The latest price target for Globus Medical (NYSE:GMED) was reported by Canaccord Genuity on December 9, 2024. The analyst firm set a price target for $92.00 expecting GMED to rise to within 12 months (a possible 8.24% upside). 36 analyst firms have reported ratings in the last year.

The latest analyst rating for Globus Medical (NYSE:GMED) was provided by Canaccord Genuity, and Globus Medical maintained their buy rating.

The last upgrade for Globus Medical Inc happened on December 2, 2024 when Morgan Stanley raised their price target to $100. Morgan Stanley previously had an equal-weight for Globus Medical Inc.

The last downgrade for Globus Medical Inc happened on February 13, 2023 when B of A Securities changed their price target from $83 to $63 for Globus Medical Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Globus Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Globus Medical was filed on December 9, 2024 so you should expect the next rating to be made available sometime around December 9, 2025.

While ratings are subjective and will change, the latest Globus Medical (GMED) rating was a maintained with a price target of $85.00 to $92.00. The current price Globus Medical (GMED) is trading at is $85.00, which is within the analyst’s predicted range.